StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > May 11 date of ownership

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon Apr 19, 2021 3:02pm

202 Views

Post# 33023201

RE:RE:RE:May 11 date of ownership

I think now would be a perfect time to put out an NR update talking about the marketing plan being contemplated, even if its a bit later down the road. Such an NR could also clear up the question of how many covid tests are being completed on a daily average basis and hints as to future corporate direction adide from CARE. It just seems to me that such updates would show investors that the company wants to stay in touch as compared to the 3 month silence lapse we had prior to the CC.

LithLover wrote: I have a lot of shares and honestly I'm waiting to see what happens in the next 3-4 weeks. I agree that a change in CEO would be a set back but on the other hand Tripp has had months/years planning for the roll out and partnerships. Wasn't it said the Care Oncology deal was in discussions for over a year. Didn't the prospectus have millions set aside for marketing?

Now I understand CoVid has changed the way many go to business, but there are still so many ways to market during these CoVid times and get the word out on Aristotle. So far its been too quiet.

Bottom line is if Tripp can't execute the business/marketing side, the board with Harry, Rory and others will find someone who can.

Maybe he would be better as a CSO and not CEO. He has a couple more months to provide shock and awe but if we don't see something in the next 3-4 weeks I think a message is going to be sent.

Liked2Think wrote: The fact this hasnt been able to tick upwards a bit has me worried. Not much volume though so easy to manipulate. Just seems like a huge mountain to regain to where we were now.

Confidence being tested but I think your right. Either some good results come out or some added interest or Tripp may be in trouble. hard to say cause the big holders usually dont like a leader change but they might be just as chokec as us normal investors now with the aristotle release disaster that it was.

Not that my votes really matters but as it sits right now he doesnt have my vote. I hope he can change my mind by then though as I think changing ceo's would just set us back further than the terrible rollout did.